Biocon’s arm receives NOC from Health Canada for Yesafili

27 Jun 2025 Evaluate

Biocon’s subsidiary -- Biocon Biologics has received Notice of Compliance (NOC) from Health Canada for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025. This approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada.

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, confirming that YESAFILI is highly similar with no clinically meaningful differences to EYLEA in terms of quality, safety, and efficacy.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

392.55 4.30 (1.11%)
05-Dec-2025 15:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.15
Dr. Reddys Lab 1275.50
Cipla 1521.80
Zydus Lifesciences 931.80
Lupin 2100.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×